A Long-Term Molecular Biomarker Registry for Patients With Acute Myeloid Leukemia and Follicular Lymphoma Observational Multi-Center Study Collecting Clinical and Molecular Data

What this Trial Is About

This research aims to gather detailed molecular and clinical data from patients with hematologic cancers like Acute Myeloid Leukemia AML and Follicular Lymphoma FL. It is an observational study designed to explore how biomarkers relate to real-world outcomes in these conditions by following patients over time. The study is conducted by Tempus AI and involves multiple patient groups with different disease stages and risks. Participants are grouped mainly into newly diagnosed AML patients and various subgroups of Follicular Lymphoma patients categorized by disease status and treatment plans. The study involves collecting blood samples and leftover tissue or bone marrow during their routine medical care and monitoring without any investigational treatments or interventions. These samples will be analyzed to understand disease progression and response. During the study, participants undergo serial blood draws and provide tissue or bone marrow samples as part of their normal care. Researchers will examine molecular markers and link these findings to clinical outcomes over five years. The study does not involve any treatments and focuses entirely on observation and data collection. Participation may last up to several years, with ongoing monitoring of health and disease status.

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies